Provided by Tiger Trade Technology Pte. Ltd.

HOOKIPA Pharma Inc.

1.00
-0.0300-2.91%
Volume:1.50K
Turnover:1.51K
Market Cap:10.04M
PE:-0.17
High:1.02
Open:1.01
Low:0.9900
Close:1.03
52wk High:1.96
52wk Low:0.7210
Shares:10.04M
Float Shares:7.03M
Volume Ratio:0.20
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8531
EPS(LYR):-3.4695
ROE:-105.79%
ROA:-45.20%
PB:0.29
PE(LYR):-0.29

Loading ...

Company Profile

Company Name:
HOOKIPA Pharma Inc.
Exchange:
PINK
Establishment Date:
2011
Employees:
85
Office Location:
350 Fifth Avenue,72nd Floor,Suite 7240,New York,New York,United States
Zip Code:
10118
Fax:
- -
Introduction:
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.